Who is sponsoring NCT02499445?

NCT02499445 is sponsored by Konkuk University Medical Center.

What condition does NCT02499445 study?

NCT02499445 studies Ischemic Heart Disease.

What drugs are being tested in NCT02499445?

Interventions: Remifentanil, sevoflurane 1, sevoflurane 2, propofol, sufentanil.

What is the status of NCT02499445?

NCT02499445 is currently COMPLETED.

Last reviewed 2015-07-15 · How we verify

Comparisons of Myocardial Injury After Using Different Anesthetics Regimens for Off-pump Coronary Artery Bypass Surgery: Remifentanil-based Versus Sevoflurane-sufentanil Balanced Regimen

NCT02499445 NA COMPLETED

In patients undergoing off-pump coronary artery bypass (OPCAB) surgery with different anesthesia regimens: remifentanil (0.75 mcg/kg/min) and propofol (TCI effect-site concentration 0.8-1.5 mcg/ml) (Group -RP); remifentanil (0.75 mcg/kg/min) and sevoflurane (end-tidal 0.8 vol%) (Group-RS), or sevoflurane (end-tidal 1.2-2.8 vol%)-sufentanil (TCI effect site concentration 0.35-0.75 ng/ml) (Group-SS), intergroup difference in the level of Troponin I (c-TnI) and creatinine kinase subtype-MB is determined before surgery (control), during vascular graft harvesting (harvesting), after completing graft construction (postgrafting), and one day after surgery (postoperative).

Details

Lead sponsor	Konkuk University Medical Center
Phase	NA
Status	COMPLETED
Enrolment	120
Start date	2007-11
Completion	2014-11

Conditions

Ischemic Heart Disease

Interventions

Remifentanil
sevoflurane 1
sevoflurane 2
propofol
sufentanil

Primary outcomes

troponin I — one day after surgery
troponin I for myocardial injury

Countries

South Korea